PIERIS PHARMACEUTICALS INC's ticker is PIRS and the CUSIP is 720795103. A total of 25 filers reported holding PIERIS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114 | +86.9% | 381,291 | +3.2% | 0.00% | – |
| Q2 2023 | $61 | -83.8% | 369,491 | -4.1% | 0.00% | – |
| Q1 2023 | $376 | -47.3% | 385,391 | -43.9% | 0.00% | -100.0% |
| Q4 2022 | $714 | -99.9% | 686,991 | -6.0% | 0.00% | 0.0% |
| Q3 2022 | $841,000 | -22.5% | 731,100 | +26.0% | 0.00% | 0.0% |
| Q2 2022 | $1,085,000 | -4.4% | 580,091 | +54.9% | 0.00% | 0.0% |
| Q1 2022 | $1,135,000 | -13.6% | 374,591 | +7.8% | 0.00% | -50.0% |
| Q4 2021 | $1,314,000 | -15.5% | 347,551 | +15.5% | 0.00% | 0.0% |
| Q3 2021 | $1,555,000 | -50.0% | 300,851 | -62.9% | 0.00% | -50.0% |
| Q2 2021 | $3,107,000 | -9.0% | 811,190 | -39.0% | 0.00% | 0.0% |
| Q1 2021 | $3,416,000 | -4.1% | 1,329,090 | -6.7% | 0.00% | 0.0% |
| Q4 2020 | $3,561,000 | +11.4% | 1,424,490 | -7.8% | 0.00% | +33.3% |
| Q3 2020 | $3,196,000 | -41.5% | 1,544,190 | -12.4% | 0.00% | -40.0% |
| Q2 2020 | $5,465,000 | +30.0% | 1,762,890 | -4.4% | 0.01% | +25.0% |
| Q1 2020 | $4,205,000 | -41.4% | 1,844,090 | -7.0% | 0.00% | -33.3% |
| Q4 2019 | $7,179,000 | -3.8% | 1,983,130 | -9.4% | 0.01% | 0.0% |
| Q3 2019 | $7,462,000 | -26.8% | 2,188,200 | +0.9% | 0.01% | -33.3% |
| Q2 2019 | $10,193,000 | +45.7% | 2,168,700 | +3.9% | 0.01% | +50.0% |
| Q1 2019 | $6,994,000 | +32.5% | 2,087,800 | +5.2% | 0.01% | 0.0% |
| Q4 2018 | $5,279,000 | -31.9% | 1,984,700 | +43.4% | 0.01% | -25.0% |
| Q3 2018 | $7,753,000 | -57.3% | 1,384,400 | -54.6% | 0.01% | -20.0% |
| Q2 2018 | $18,153,000 | +74.0% | 3,052,400 | +99.5% | 0.01% | -9.1% |
| Q1 2018 | $10,433,000 | +112.6% | 1,529,800 | +135.3% | 0.01% | +120.0% |
| Q4 2017 | $4,908,000 | +114.6% | 650,100 | +63.7% | 0.01% | +66.7% |
| Q3 2017 | $2,287,000 | +290.3% | 397,100 | +242.6% | 0.00% | +200.0% |
| Q2 2017 | $586,000 | -11.3% | 115,900 | -54.4% | 0.00% | 0.0% |
| Q1 2017 | $661,000 | +736.7% | 254,400 | +490.3% | 0.00% | – |
| Q3 2016 | $79,000 | – | 43,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 9,775,849 | $2,913,203 | 1.93% |
| Aquilo Capital Management, LLC | 3,303,190 | $984,351 | 0.89% |
| CM Management, LLC | 649,400 | $193,521 | 0.20% |
| BVF INC/IL | 20,609,863 | $6,141,739 | 0.17% |
| WEALTH EFFECTS LLC | 11,700 | $3,487 | 0.00% |
| NJ State Employees Deferred Compensation Plan | 30,000 | $8,940 | 0.00% |
| HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 14,000 | $4,172 | 0.00% |
| ACADIAN ASSET MANAGEMENT LLC | 962,358 | $286 | 0.00% |
| TWO SIGMA ADVISERS, LP | 24,400 | $7,271 | 0.00% |
| Tower View Wealth Management LLC | 1,000 | $0 | 0.00% |